Navigation Links
Poniard Pharmaceuticals to Host Fourth Quarter and Year-End 2008 Financial Results Conference Call on March 12
Date:3/5/2009

SOUTH SAN FRANCISCO, Calif., March 5 /PRNewswire-FirstCall/ -- Poniard Pharmaceuticals, Inc. (Nasdaq: PARD), a biopharmaceutical company focused on innovative oncology therapies, today announced that it will hold a conference call to discuss the Company's fourth quarter and year-end financial results and provide a corporate update, including ongoing development activities for picoplatin, the Company's lead product candidate.

Jerry McMahon, Ph.D., chairman and chief executive officer, Ronald A. Martell, president and chief operating officer, Greg Weaver, chief financial officer, and Robert De Jager, M.D., FACP, chief medical officer, will host the call beginning at 8:30 a.m. Eastern Time (5:30 a.m. Pacific Time) on Thursday, March 12. A press release for the fourth quarter and year-ended December 31, 2008, will be released before market opening on March 12.

To participate in the live call by telephone, please dial 877-719-9791 from the U.S. or 719-325-4811 for international callers. In addition, the live conference call is being webcast and can be accessed on the "Events" page of the "News & Events" section of the Company's website at http://www.poniard.com. A replay of the webcast will be available on the Company's website for 10 days.

About Poniard Pharmaceuticals

Poniard Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of innovative oncology products to impact the lives of people with cancer. Picoplatin, the Company's lead platform product candidate, is a new generation platinum chemotherapy. To date, clinical studies suggest that picoplatin has an improved safety profile relative to existing platinum-based cancer therapies. Picoplatin is designed to overcome platinum resistance associated with chemotherapy in solid tumors, and is being studied in multiple cancer indications, combinations and formulations. Clinical trials of intravenous picoplatin include a Phase 3 trial in small cell lung cancer and Phase 2 trials in metastatic colorectal and castration-resistant prostate cancers (also known as hormone-refractory prostate cancer), as well as a clinical trial of oral picoplatin in solid tumors. For additional information please visit http://www.poniard.com.

(C) 2009 Poniard Pharmaceuticals, Inc. All Rights Reserved.

Poniard and Poniard Pharmaceuticals are trademarks of Poniard Pharmaceuticals, Inc.


'/>"/>
SOURCE Poniard Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Poniard Pharmaceuticals Announces New Efficacy and Safety Data from a Phase 2 Picoplatin Trial in Patients with Prostate Cancer
2. Poniard Pharmaceuticals to Present at the BIO CEO & Investor Conference
3. Poniard Pharmaceuticals Announces Positive Tumor Response and Neuropathy Data from Phase 2 Clinical Trial of Picoplatin in Metastatic Colorectal Cancer
4. Poniard Pharmaceuticals to Present Data from Phase 2 Clinical Trials of Picoplatin in Colorectal and Prostate Cancers
5. Poniard Pharmaceuticals Announces Commercial Supply Agreement for Picoplatin
6. Poniard Pharmaceuticals to Host Third Quarter 2008 Financial Results Conference Call on October 30
7. Poniard Announces Positive Incremental Efficacy and Safety Data from Phase 2 Picoplatin Trial in Patients With Metastatic Colorectal Cancer
8. Poniard Announces Positive Incremental Efficacy and Safety Data From Ongoing Phase 2 Picoplatin Trial in Hormone-Refractory Prostate Cancer
9. Poniard Pharmaceuticals to Present at the JMP Securities Healthcare Focus Conference
10. Poniard Pharmaceuticals Announces Upcoming Conference Participation
11. Poniard Pharmaceuticals to Present at the 4th Annual Moores UCSD Cancer Center Translational Oncology Symposium
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2016)... More than $4.3 million was raised last night ... ). The gala was held at the American Museum of ... and honored Alan Alda and P. ... medicine and the public understanding of science. Since the first ... has raised $40 million for the Laboratory,s research and education ...
(Date:12/2/2016)... LOS ANGELES , Dec. 2, 2016 ... research and development company specializing in oncology, today announced ... a noted sarcoma surgeon, industry consultant, and private healthcare ... Brien is a healthcare leader with clinical and strategic ... Kriegsman , CytRx,s Chairman and CEO. "As one of ...
(Date:12/2/2016)... ... December 01, 2016 , ... ... value of DNA microarray comparative genomic hybridization (array CGH) for HER2 genomic ... Symposium. Using molecular test results from tumors with previously documented positive, negative, ...
(Date:12/2/2016)... York, NY (PRWEB) , ... December 01, 2016 , ... ... event is expanding to three days and will take place on February 1-3, 2017 ... (GSK) and Dr James Gulley (NCI), the program provides a unique 360-degree approach, which ...
Breaking Biology Technology:
(Date:6/27/2016)... , June 27, 2016 Research and Markets ... America 2016-2020" report to their offering. ... North America to grow at a CAGR of 12.28% ... prepared based on an in-depth market analysis with inputs from industry ... over the coming years. The report also includes a discussion of ...
(Date:6/22/2016)... ANGELES , June 22, 2016 /PRNewswire/ ... identity management and verification solutions, has partnered ... edge software solutions for Visitor Management, Self-Service ... provides products that add functional enhancements ... partnership provides corporations and venues with an ...
(Date:6/21/2016)... 2016 NuData Security announced today that Randy ... principal product architect and that Jon Cunningham ... development. Both will report directly to Christopher ... reflect NuData,s strategic growth in its product and ... demand and customer focus values. ...
Breaking Biology News(10 mins):